Protecting Xarelto: Why the New FDA Review Process Will Matter
This article was originally published in RPM Report
Executive Summary
The Xarelto advisory committee offers an interesting case study for considering how the new drug review process outlined in the PDUFA V agreement may work to help sponsors.